Back to Search Start Over

Data from Transporter-Mediated Protection against Thiopurine-Induced Hematopoietic Toxicity

Authors :
John D. Schuetz
Mary Relling
William Evans
Erin Schuetz
Balasubramanian Poonkuzhali
Richard B. Kim
Catia Marzolini
Hiromitsu Nakauchi
Meyling Cheok
Kelli Boyd
Weinan Du
Mark Leslie
Jessica Morgan
Deepa Nachagari
Kazumasa Takenaka
Matthias Schwab
Partha Krishnamurthy
Publication Year :
2023
Publisher :
American Association for Cancer Research (AACR), 2023.

Abstract

Thiopurines are effective immunosuppressants and anticancer agents, but intracellular accumulation of their active metabolites (6-thioguanine nucleotides, 6-TGN) causes dose-limiting hematopoietic toxicity. Thiopurine S-methyltransferase deficiency is known to exacerbate thiopurine toxicity. However, many patients are highly sensitive to thiopurines for unknown reasons. We show that multidrug-resistance protein 4 (Mrp4) is abundant in myeloid progenitors and tested the role of the Mrp4, an ATP transporter of monophosphorylated nucleosides, in this unexplained thiopurine sensitivity. Mrp4-deficient mice experienced Mrp4 gene dosage-dependent toxicity caused by accumulation of 6-TGNs in their myelopoietic cells. Therefore, Mrp4 protects against thiopurine-induced hematopoietic toxicity by actively exporting thiopurine nucleotides. We then identified a single-nucleotide polymorphism (SNP) in human MRP4 (rs3765534) that dramatically reduces MRP4 function by impairing its cell membrane localization. This SNP is common (>18%) in the Japanese population and indicates that the increased sensitivity of some Japanese patients to thiopurines may reflect the greater frequency of this MRP4 SNP. [Cancer Res 2008;68(13):4983–9]

Details

Database :
OpenAIRE
Accession number :
edsair.doi...........a7ad23ef836d2d01696ec851f11a0655
Full Text :
https://doi.org/10.1158/0008-5472.c.6497370